Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicholas Piramal India Inks R&D Deal With Merck

This article was originally published in PharmAsia News

Executive Summary

Mumbai-based Nicholas Piramal India Limited inked a research and development deal with Delhi-based Merck subsidiary MSD Pharmaceuticals, NPIL announced Nov. 19

You may also be interested in...



Covance R&D Deal Meshes With Lilly’s “FIPNet” Model

Lilly has deepened its commitment to its fully integrated pharmaceutical network strategy, most recently adding a deal with the contract research organization Covance

Covance R&D Deal Meshes With Lilly’s “FIPNet” Model

Lilly has deepened its commitment to its fully integrated pharmaceutical network strategy, most recently adding a deal with the contract research organization Covance

PharmAsia News Spotlight On India: Smaller R&D Units To Dominate India - Study

MUMBAI - India, which has now found a respectable place for itself on the global drug R&D map, could increasingly see smaller dedicated R&D units power the escalating research momentum in the country

Related Content

UsernamePublicRestriction

Register

LL1126271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel